A randomised phase II/III multi-centre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus

Trial Profile

A randomised phase II/III multi-centre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Cetuximab (Primary) ; Capecitabine; Cisplatin
  • Indications Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms SCOPE-1; SCOPE1
  • Most Recent Events

    • 14 Feb 2017 Final results of long term outcomes published in the British Journal of Cancer.
    • 14 Nov 2014 United Kingdom Clinical Research Network reports accrual to date changed to 61%.
    • 26 Jan 2013 Primary endpoint 'Failure-free-survival-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top